Tag: cancer

cancer patient

Mayo Clinic study provides clarity on use of anticoagulants to treat...

A study by Mayo Clinic researchers provides some clarity on the use of direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, to treat...
cancer patient

High thrombotic risk in cancer patients receiving immunotherapy

According to a recent study, patients with cancer under immune checkpoint inhibitor therapy are at high risk of thromboembolism, especially venous thromboembolism (VTE). Furthermore,...
cancer patient

Comparable risk of recurrent VTE between patients with unprovoked VTE and...

Patients with venous thromboembolism (VTE) carry a high risk of recurrence. Accordingly, a 16-year Danish prospective cohort study of nearly 74,000 patients with incident VTE...
cancer patient

DOACs show promise over heparin injections in meta-analysis comparing cancer-associated VTE...

A recent meta-analysis found that direct oral anticoagulants (DOACs) appear to be a “reasonable alternative” to low molecular weight heparin (LMWH) for the treatment...
Human colorectal cancer cells

Virtual ACC: Caravaggio study confirms noninferiority of apixaban to heparin for...

It has been found that oral apixaban is noninferior to subcutaneous dalteparin for the treatment of cancer-related venous thromboembolism (VTE), as revealed by Giancarlo...
Steven Dean lymphoedema

Chronic venous insufficiency identified as a leading cause of lower extremity...

A retrospective analysis of patients diagnosed with lower extremity lymphoedema, and treated in a cancer-affiliated physical therapy department, has found that chronic venous insufficiency...

Cancer-associated VTE trial sees “lower rate of recurrent VTE with edoxaban...

Daiichi Sanyoko has announced the results from their Hokusai-VTE CANCER trial evaluating the direct oral anticoagulant edoxaban for treatment of venous thromboembolism (VTE) in...